get a key
steadybase-$ company RIGL
account_id none on file
legal_name Rigel Pharmaceuticals Inc
ticker RIGL
cik 1034842
domain rigel.com
entry_point_account_id none on file
name Rigel Pharmaceuticals Inc.
exchange Nasdaq
sector Health Care
hq South San Francisco, CA, United States
calls 1 filings 60 executives 5 family 0
why_now
than 2028. after which we will begin to shift our focus to the potential launch of R289 in lower-risk MVS and other potential indications. Consistent with our prior transactions, we are prioritizing assets that leverage our existing commercial infrastructure, which will enable

Aug 4, 2026 / receipt

calls
We are expanding 40% from 39 to 55 territories, giving us the capacity to call on the majority of prescribers who treat ITP and reduce travel time for our team, allowing them to call on their customers more frequently.

Aug 3, 2021 / receipt, needs a key / Dave Santos, Chief Commercial Officer | earnings call 2021-08-03 | transcript 66b0554d-7011-4873-9086-cf7839e66fed | chars 8522-8740 | segment 8

filings
Anticipate will report positive net income for the full year 2026, while funding existing and new clinical development programs

ir_statement / Sep 17, 2026 / receipt

Interest expense (1,433) (1,853)

ir_statement / Sep 17, 2026 / receipt

Selling, general and administrative 30,651 27,715

ir_statement / Sep 17, 2026 / receipt

restructured its credit relationship with MidCap Financial to replace its existing term loan credit facility with a revolving credit facility

ir_statement / Sep 16, 2026 / receipt

Fully resourced field teams to meet customer needs in the field

ir_statement / Sep 16, 2026 / receipt

Potential for VEPPANU to become Rigel’s largest commercial product

ir_statement / Sep 16, 2026 / receipt

Successful track record of taking newly acquired assets to market quickly and efficiently

ir_statement / Sep 16, 2026 / receipt

In early May, Rigel restructured its credit relationship with MidCap Financial to replace its existing term loan credit facility with a revolving credit facility

ir_statement / Sep 16, 2026 / receipt

In mid-April, Eli Lilly notified Rigel that it will terminate the collaboration agreement

ir_statement / Sep 16, 2026 / receipt

Commercially launch VEPPANU in August

ir_statement / Sep 16, 2026 / receipt

Leverage existing commercial and operating infrastructure during integration of vepdegestrant to drive financial synergies

ir_statement / Sep 16, 2026 / receipt

In early May, Rigel restructured its credit relationship with MidCap Financial to replace its existing term loan credit facility with a revolving credit facility

ir_statement / Sep 16, 2026 / receipt

executives
Dave Santos Chief Commercial Officer - receipt
Keith Katkin director - receipt
Nelson Cabatuan Interim Principal Accounting Officer - receipt
Raul R. Rodriguez director - receipt
Wolfgang Dummer Chief Medical Officer - receipt
familynone on file
upcoming
2026-11-03 earnings call scheduled ir
changes
2017-12-15 Interim Principal Accounting Officer, appointed sec_8k
2017-02-24 director, appointed sec_8k
2017-02-24 director, departed sec_8k
2015-07-01 director, appointed sec_8k
2014-11-24 Chief Executive Officer, appointed sec_8k
mcp_package_hint
steadybase-$